Aicar CAS 2627-69-2 Cardiovascular Diseases Treatment Acades

Email:[email protected]
Skype:live:kathelin_4
WhataApp:+86-188 7222 0706

MOQ:10G

Contact with me if any interested.

Aicar CAS 2627-69-2 Cardiovascular Diseases Treatment Acadesine
Aicar Spec.
Acadesine
Alias: AICAR; AICA-RIBOSIDE; AMPK; Z-RIBOSIDE
CAS: 2627-69-2
EINECS: 220-097-5
Molecular Formula: C9H14N4O5
Molecular Weight: 258.23
Assay: 98%
Apperance: White or off-white powder.
Grade:Pharmaceutical Grade
Usage: Pharmaceutical intermediates. For the treatment of cardiovascular diseases.acts by entering nucleoside pools, significantly increasing levels of
adenosine during periods of ATP breakdown

Functions:
AICAR (AICA-Riboside) strongly inhibits the transcription of PPAR&alpha and the coactivation of PPAR&alpha. In adipocyte studies it has been shown to antagonize lipolysis induced by isoprenaline and has been suggested for use in kinase cascade research. Additionally, research indicates that AICAR blocks the differentiation of 3T3-L1 (sc-2243) adipocytes. Studies demonstrate that AICAR can mimic the activity of insulin (sc-211647) by activating AMPK (AMP-activated protein kinase), and affecting the expression of PEPCK-M (PEPCK) and glucose-6-phosphatase (G6Pase). The 5-aminoimidazole-4-carboxamide ribonucleoside (ZMP) is the monophosphorylated derivative of AICA-Riboside, and it can serve as the substrate for the aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC). AICAR is an inhibitor of Hsp90, mTOR and p70 S6 Kinase.